Reference | Lugsomya2018 (20009)

Routine Prophylactic Antimicrobial Use Is Associated with Increased Phenotypic and Genotypic Resistance in Commensal Escherichia coli Isolates Recovered from Healthy Fattening Pigs on Farms in Thailand.


Lugsomya, Kittitat; Chatsuwan, Thanitta; Niyomtham, Waree; Tummaruk, Padet; Hampson, David J.; Prapasarakul, Nuvee (Thailand)

Microbial Drug Resistance (2018)

Reference


Samples were collected from 25 farms located across five Provinces of Thailand. The farms were selected based on their antimicrobial usage patterns. Twelve farms routinely used PAs; two only used antimicrobials therapeutically, TAs; and 11 small farms had never used antimicrobials, NAs. For the 12 PA farms, a routine in-feed antimicrobial use program had been followed for at least 2 years for endemic bacterial disease prophylaxis. A total of 102 fecal samples from individual 18- to 20- week-old fattening pigs with a normal appearance and no recent history of enteric or respiratory disease, or TA treatment, were obtained from the farms (7–10 samples per farm).A total of 70 fecal samples were obtained from similar fattening pigs on two TA farms that did not use PAs and only used the injectable antimicrobial enrofloxacin or gentamicin under veterinary prescription for individual treatment of specific clinical cases where the sick pigs were kept in isolation. Another 67 samples were collected from fattening pigs on the 11 NA farms, where there was no access to or use of antimicrobials or vaccination.

For each pig, at least 5 g of rectal feces was collected directly into a sterile container and delivered to the laboratory at 4C.

AST Method: None

Reference explicitly reports AST breakpoints: False

Reference reports using a MIC table: False

Is Excluded: False

Country Sub-Region Sub-Region Detail
Thailand Other (Other) Across 5 provinces
ID Note Resolution

Factors


Title Host Host Production Stage Description ROs
Prophylactic ampicillin use Swine Grower-finisher Farm Ampicillin use broken up by treatment group 1
Prophylactic AMU Swine Grower-finisher Farm Resistance outcome is blaTEM gene 1
Therapeutic tiamulin use Swine Grower-finisher Farm Tiamulin use broken up by treatment group 1
Therapeutic amikacin use Swine Grower-finisher Farm Amikacin use broken up by treatment group 1
Therapeutic chloramphenicol use Swine Grower-finisher Farm Chloramphenicol use broken up by treatment group 1
Prophylactic imipenem use Swine Grower-finisher Farm Imipenem use broken up by treatment group 1
Therpeutic AMU Swine Grower-finisher Farm Resistance outcome is blaTEM gene 1
Prophylactic tobramycin use Swine Grower-finisher Farm Tobramycin use broken up by treatment group 1
Prophylactic AMU Swine Grower-finisher Farm Resistance outcome is catA gene 1
Therpeutic AMU Swine Grower-finisher Farm Resistance outcome is blaCTX-M9 gene 1
Therapeutic piperacillin use Swine Grower-finisher Farm Piperacillin use broken up by treatment group 1
Prophylactic marbofloxacin use Swine Grower-finisher Farm Marbofloxacin use broken up by treatment group 1
Therapeutic AMU Swine Grower-finisher Farm Resistance outcome is sul3 gene 1
Prophylactic cefpodoxime use Swine Grower-finisher Farm Cefpodoxime use broken up by treatment group 1
Therapeutic AMU Swine Grower-finisher Farm Resistance outcome is dfrA12 gene 1
Prophylactic AMU Swine Grower-finisher Farm Resistance outcome is aadA2 gene 1
Therapeutic ampicillin use Swine Grower-finisher Farm Ampicillin use broken up by treatment group 1
Prophylactic AMU Swine Grower-finisher Farm Resistance outcome is dfrA12 gene 1
Therapeutic AMU Swine Grower-finisher Farm Resistance outcome is aadB gene 1
Therapeutic tetracycline use Swine Grower-finisher Farm Tetracylcine use broken up by treatment group 1
Prophylactic tetracycline use Swine Grower-finisher Farm Tetracylcine use broken up by treatment group 1
Therapeutic cefpodoxime use Swine Grower-finisher Farm Cefpodoxime use broken up by treatment group 1
Prophylactic amoxicillin use Swine Grower-finisher Farm Amoxicillin use broken up by treatment group 1
Therapeutic AMU Swine Grower-finisher Farm Resistance outcome is sul1 gene 1
Therapeutic AMU Swine Grower-finisher Farm Resistance outcome is aadA1 gene 1
Prophylactic AMU Swine Grower-finisher Farm Resistance outcome is dfrA10 gene 1
Prophylactic tiamulin use Swine Grower-finisher Farm Tiamulin use broken up by treatment group 1
Therapeutic AMU Swine Grower-finisher Farm Resistance outcome is aadA2 gene 1
Therapeutic ceftiofur use Swine Grower-finisher Farm Ceftiofur use broken up by treatment group 1
Prophylactic AMU Swine Grower-finisher Farm Resistance outcome is tetB gene 1
Therapeutic AMU Swine Grower-finisher Farm Resistance outcome is Int1 gene 1
Prophylactic nitrofurantoin use Swine Grower-finisher Farm Nitrofurantoin use broken up by treatment group 1
Therapeutic gentamicin use Swine Grower-finisher Farm Gentamicin use broken up by treatment group 1
Therapeutic cefpirome use Swine Grower-finisher Farm Cefpirome use broken up by treatment group 1
Prophylactic AMU Swine Grower-finisher Farm Resistance outcome is sul1 gene 1
Prophylactic gentamicin use Swine Grower-finisher Farm Gentamicin use broken up by treatment group 1
Prophylactic Amoxicillin/clavulanic acid use Swine Grower-finisher Farm Amoxicillin/clavulanic acid use broken up by treatment group 1
Prophylactic AMU Swine Grower-finisher Farm Resistance outcome is sul2 gene 1
Prophylactic cefpirome use Swine Grower-finisher Farm Cefpirome use broken up by treatment group 1
Prophylactic AMU Swine Grower-finisher Farm Resistance outcome is aadA1 gene 1
Prophylactic AMU Swine Grower-finisher Farm Resistance outcome is sul3 gene 1
Therapeutic AMU Swine Grower-finisher Farm Resistance outcome is cmlA gene 1
Prophylactic ceftiofur use Swine Grower-finisher Farm Ceftiofur use broken up by treatment group 1
Therapeutic Amoxicillin/clavulanic acid use Swine Grower-finisher Farm Amoxicillin/clavulanic acid use broken up by treatment group 1
Prophylactic AMU Swine Grower-finisher Farm Resistance outcome is tetA gene 1
Prophylactic AMU Swine Grower-finisher Farm Resistance outcome is aadB gene 1
Therapeutic enrofloxacin use Swine Grower-finisher Farm Enrofloxacin use broken up by treatment group 1
Prophylactic cefalexin use Swine Grower-finisher Farm Cefalexin use broken up by treatment group 1
Prophylactic AMU Swine Grower-finisher Farm Resistance outcome is dfrA1 gene 1
Therapeutic AMU Swine Grower-finisher Farm Resistance outcome is dfrA1 gene 1
Prophylactic piperacillin use Swine Grower-finisher Farm Piperacillin use broken up by treatment group 1
Therapeutic amoxicillin use Swine Grower-finisher Farm Amoxicillin use broken up by treatment group 1
Prophylactic amikacin use Swine Grower-finisher Farm Amikacin use broken up by treatment group 1
Prophylactic AMU Swine Grower-finisher Farm Resistance outcome is blaCTX-M-1 gene 1
Therapeutic imipenem use Swine Grower-finisher Farm Imipenem use broken up by treatment group 1
Therapeutic AMU Swine Grower-finisher Farm Resistance outcome is catB gene 1
Therapeutic AMU Swine Grower-finisher Farm Resistance outcome is dfrA10 gene 1
Prophylactic AMU Swine Grower-finisher Farm Resistance outcome is cmlA gene 1
Prophylactic Trimethoprim/sulfamethoxazole use Swine Grower-finisher Farm Trimethoprim/sulfamethoxazole use broken up by treatment group 1
Therapeutic tobramycin use Swine Grower-finisher Farm Tobramycin use broken up by treatment group 1
Prophylactic AMU Swine Grower-finisher Farm Resistance outcome is blaCTX-M9 gene 1
Therapeutic cefalexin use Swine Grower-finisher Farm Cefalexin use broken up by treatment group 1
Therapeutic nitrofurantoin use Swine Grower-finisher Farm Nitrofurantoin use broken up by treatment group 1
Therapeutic AMU Swine Grower-finisher Farm Resistance outcome is tetB gene 1
Prophylactic enrofloxacin use Swine Grower-finisher Farm Enrofloxacin use broken up by treatment group 1
Therapeutic AMU Swine Grower-finisher Farm Resistance outcome is tetA gene 1
Therapeutic AMU Swine Grower-finisher Farm Resistance outcome is ESBP E. coli gene 1
Prophylactic AMU Swine Grower-finisher Farm Resistance outcome is Int1 gene 1
Prophylactic AMU Swine Grower-finisher Farm Resistance outcome is ESBP E. coli gene 1
Prophylactic AMU Swine Grower-finisher Farm Resistance outcome is catB gene 1
Therapeutic AMU Swine Grower-finisher Farm Resistance outcome is blaCTX-M-1 gene 1
Prophylactic chloramphenicol use Swine Grower-finisher Farm Chloramphenicol use broken up by treatment group 1
Therapeutic Trimethoprim/sulfamethoxazole use Swine Grower-finisher Farm Trimethoprim/sulfamethoxazole use broken up by treatment group 1
Therapeutic AMU Swine Grower-finisher Farm Resistance outcome is sul2 gene 1
Therapeutic marbofloxacin use Swine Grower-finisher Farm Marbofloxacin use broken up by treatment group 1
Therapeutic AMU Swine Grower-finisher Farm Resistance outcome is catA gene 1